Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | KITE-363 |
Trade Name | |
Synonyms | KITE 363|KITE363 |
Drug Descriptions |
KITE-363 comprises autologous T-lymphocytes engineered to express chimeric antigen receptors (CARs) targeting CD19 and CD20 as well as the CD28 and 4-1BB costimulatory domains, which potentially results in killing of tumor cells expressing CD19 and/or CD20 (J Clin Oncol 40, no. 16_suppl (June 01, 2022) TPS7579). |
DrugClasses | CD19 Immune Cell Therapy 62 CD20 Immune Cell Therapy 11 |
CAS Registry Number | NA |
NCIT ID | C181943 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Cyclophosphamide + Fludarabine + KITE-363 | Cyclophosphamide Fludarabine KITE-363 | 0 | 1 |
KITE-363 | KITE-363 | 0 | 0 |